Daniel Geynisman discusses the potential for the novel tyrosine kinase inhibitor sitravatinib and the HIF-2α inhibitor MK-6482 to change the treatment paradigm in advanced clear-cell renal cell carcinoma (4:47).
16-02-2020 | ASCO GU 2020 | Conference coverage | Video